RxDoctor Payments Data

Jeremy Bergamo, MD

Urology · Sarasota, FLNPI 1619324019

Payments from drug & device makers

$3,911in general payments, 2019–2025

Across 129 payments — averaging $30.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$474
  • Coloplast$392
  • Axonics, Inc.$358
  • AbbVie$307
  • Johnson & Johnson$242
  • Teleflex LLC$222
  • plus $2K from 27 others

What the payments were for

  • Food & beverage$3,911100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,911 in reported general payments places this provider in the 45th percentile of 935 urology providers in Florida.

See all urology providers in Florida

Medicare billing

Part B allowed, 2024
$396,820
Medicare patients
1,059
Services billed
13,901

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide49$503,279
OrgovyxRelugolix91$241,938
ErleadaApalutamide16$210,393
MyrbetriqMirabegron148$110,618
GemtesaVibegron48$38,077
Tamsulosin Hcl787$9,803
Solifenacin Succinate64$7,373
Potassium Citrate ErPotassium Citrate34$5,233
Testosterone12$5,156
Testosterone Cypionate90$4,935
Finasteride381$4,300
Trospium Chloride ErTrospium Chloride19$2,766
Cephalexin395$2,162
Trimethoprim50$1,917
Alfuzosin Hcl ErAlfuzosin Hcl61$1,617

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$90$613,897197 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$149$280,015139 claims
Johnson & JohnsonErleada$242$210,39316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 935 urology providers in Florida.

Other urology in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →